

Literaturverzeichnis

Hamburger Ärzteblatt 11 | 2017

Seite 1

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aeckhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 12-16: Erhöhter TSH-Wert in der Hausarztpraxis. Von Jeannine Schübel, Dr. Dipl.-Soz. Karen Voigt

1. Schübel J, Voigt K, Bründel K-H, Bergmann A. Erhöhter TSH-Wert in der Hausarztpraxis (DEGAM-Leitlinie Nr. 18). www.degam.de/degam-leitlinien-379.html [letzter Zugriff am 18.1.2017]
2. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Leitlinien-Detailansicht: Erhöhter TSH-Wert in der Hausarztpraxis. <http://www.awmf.org/leitlinien/detail/II/053-046.html> [letzter Zugriff am 5.10.2017]
3. Hamilton TE, Davis S, Onstad L, Kopecky KJ. Thyrotropin levels in a population with no clinical, autoantibody, or ultrasonographic evidence of thyroid disease: implications for the diagnosis of subclinical hypothyroidism. *J Clin Endocrinol Metab.* 2008; 93:1224-30.
4. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab.* 2002;87:489-99.
5. Fink H, Hintze G. [Autoimmune thyroiditis (Hashimoto's thyroiditis): current diagnostics and therapy]. *Med Klin.* 2010;105:485-93.
6. Zöphel K, Gruning T, Roggenbuck D, Wunderlich G, Kotzerke J. On specificity of 2nd generation TSH receptor autoantibody measurements. *Clin lab.* 2008; 54:243-9.
7. Vanderpump MPJ, Tunbridge WMG, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. *Clin Endocrinol.* 1995;43:55-68.
8. Meyerovitch J, Rotman-Pikielny P, Sherf M, Battat E, Levy Y, Surks MI. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. *Arch Intern Med.* 2007;167:1533-8.
9. Khandelwal D, Tandon N. Overt and subclinical hypothyroidism: who to treat and how. *Drugs.* 2012;72:17-33.
10. Endocrine Society-Thyroid ultrasounds | Choosing Wisely, <http://www.choosingwisely.org/societies/endocrine-society/> [letzter Zugriff am 18.1.2017]
11. Pham CB, Shaughnessy AF. Should we treat subclinical hypothyroidism? *BMJ.* 2008;337:a834.
12. Vaidya B, Pearce SHS. Management of hypothyroidism in adults. *BMJ.* 2008; 337:a801
13. Viniol A, Bosner S, Baum E, Donner-Banzhoff N. Forgotten drugs: long-term prescriptions of thyroid hormones - a cross-sectional study. *Int J Gen Med.* 2013; 6:329-34.
14. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI et al.: Clinical Practice Guidelines for Hypothyroidism in Adults: Co-sponsored by American Association of Clinical Endocrinologists and the American Thyroid Association. *Endocr Pract.* 2012;1-207.

S. 28-30: Arterienembolisation bei benigner Prostatahyperplasie.

Von Dr. Paul Steffen, Dr. Murat Karul, Dr. Fernandez De la Maza, Prof. Dr. Christian R. Habermann

1. Berges RR, Pientka L, Höfner K, Senge T, Jonas U. Male lower urinary tract symptoms and related health care seeking in Germany. *Eur Urol.* 2001;39(6):682–7.
2. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). *European Urology.* 2005. p. 824–37.
3. Bilhim T, Pisco JM, Rio Tinto H, Fernandes L, Pinheiro LC, Furtado A, et al. Prostatic arterial supply: Anatomic and imaging findings relevant for selective arterial embolization. *J Vasc Interv Radiol.* Elsevier Inc.; 2012;23(11):1403–15.

Literaturverzeichnis

Hamburger Ärzteblatt 11 | 2017

Seite 2

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

4. Bilhim T, Pisco JM, Furtado A, Casal D, Pais D, Pinheiro LC, et al. Prostatic arterial supply: Demonstration by multirow detector Angio CT and Catheter Angiography. *Eur Radiol.* 2011;21(5):1119–26.
5. Pisco JM, Pinheiro LC, Bilhim T, Duarte M, Mendes JR, Oliveira AG. Prostatic arterial embolization to treat benign prostatic hyperplasia. *J Vasc Interv Radiol.* Elsevier Inc.; 2011;22(1):11–9.
6. Bagla S, Rholl KS, Sterling KM, Van Breda A, Papadouris D, Cooper JM, et al. Utility of cone-beam CT imaging in prostatic artery embolization. *J Vasc Interv Radiol.* Elsevier; 2013;24(11):1603–7.
7. Bilhim T, Pisco J, Rio Tinto H, Fernandes L, Campos Pinheiro L, Duarte M, et al. Unilateral versus bilateral prostatic arterial embolization for lower urinary tract symptoms in patients with prostate enlargement. *Cardiovasc Intervent Radiol.* 2013;36(2):403–11.
8. Bagla S, Martin CP, Van Breda A, Sheridan MJ, Sterling KM, Papadouris D, et al. Early results from a united states trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. *J Vasc Interv Radiol.* Elsevier; 2014;25(1):47–52.
9. Gao Y, Huang Y, Zhang R, Yang Y, Zhang Q, Hou M, et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate – a prospective, randomized, and controlled clinical trial. *Radiology.* 2014;270(3):920–8.
10. Wang M, Guo L, Duan F, Yuan K, Zhang G, Li K, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms as a result of large benign prostatic hyperplasia: A prospective single-center investigation. *Int J Urol.* 2015;22(8):766–72.
11. Carnevale FC, Antunes A a. Prostatic artery embolization for enlarged prostates due to benign prostatic hyperplasia. How i do it. *Cardiovasc Intervent Radiol.* 2013;36(6):1452–63.
12. Lebdai S, Delongchamps NB, Sapoval M, Robert G, Amouyal G, Thiounn N, et al. Early results and complications of prostatic arterial embolization for benign prostatic hyperplasia. *World J Urol.* 2016;34(5):625–32.
13. Compagnone G, Giampalma E, Domenichelli S, Renzulli M, Golfieri R. Calculation of conversion factors for effective dose for various interventional radiology procedures. *Med Phys.* 2012;39(5):2491.
14. Pisco JM, Rio Tinto H, Campos Pinheiro L, Bilhim T, Duarte M, Fernandes L, et al. Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: Results of short- and mid-term follow-up. *Eur Radiol.* 2013;23(9):2561–72.
15. Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes A a., Srougi M. Transurethral Resection of the Prostate (TURP) Versus Original and PErFecTED Prostate Artery Embolization (PAE) Due to Benign Prostatic Hyperplasia (BPH): Preliminary Results of a Single Center, Prospective, Urodynamic-Controlled Analysis. *Cardiovasc Intervent Radiol.* 2016;39(1):44–52.
16. Amouyal G, Thiounn N, Pellerin O, Yen-Ting L, Del Giudice C, Dean C, et al. Clinical Results After Prostatic Artery Embolization Using the PErFecTED Technique: A Single-Center Study. *Cardiovasc Intervent Radiol.* 2016;39(3):367–75.
17. Wang MQ, Guo LP, Zhang GD, Kai Y, Duan F, Yan JY, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population. *BMC Urol.* 2015;15(8):33–44.
18. Pisco JM, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa N V, et al. Medium- and Long-Term Outcome of Prostate Artery Embolization for Patients with Benign Prostatic Hyperplasia: Results in 630 Patients. *J Vasc Interv Radiol.* 2016;27(8):1115–22.

Literaturverzeichnis

Hamburger Ärzteblatt 11 | 2017

Seite 3

Weidestr. 122 b
22083 Hamburg
Redaktion
E-Mail: verlag@aekhh.de
Tel.: (040) 20 22 99 – 205
Fax: (040) 20 22 99 – 400

19. Mitchell ME, Waltman AC, Athanasoulis CA, Kerr WS, Dretler SP. Control of massive prostatic bleeding with angiographic techniques. *J Urol.* 1976;115(6):692–5.
20. Barbieri A, Simonazzi M, Marcato C, Larini P, Barbagallo M, Frattini A, et al. Massive hematuria after transurethral resection of the prostate: Management by intra-arterial embolization. *Urol Int.* 2002;69(4):318–20.
21. Park YH, Lee JH, Kim HH. Severe bleeding after laparoscopic radical prostatectomy: successful management with trans-arterial embolization. *J Endourol.* 2008;22(12):2687–9.
22. Demeritt JS, Elmasri FF, Esposito MP, Rosenberg GS. Case Report Relief of Benign Prostatic Hyperplasia- Transarterial Polyvinyl Alcohol Prostate Embolization 1. 2000;767–70.
23. Carnevale FC, Antunes AA, Da Motta Leal Filho JM, De Oliveira Cerri LM, Baroni RH, Marcelino ASZ, et al. Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: Preliminary results in two patients. *Cardiovasc Intervent Radiol.* 2010;33(2):355–61.
24. De Assis AM, Moreira AM, De Paula Rodrigues VC, Yoshinaga EM, Antunes AA, Harward SH, et al. Prostatic artery embolization for treatment of benign prostatic hyperplasia in patients with prostates > 90 g: A prospective single-center study. *Journal of Vascular and Interventional Radiology.* 2015. p. 87–93.
25. Kurbatov D, Russo GI, Lepetukhin A, Dubsky S, Sitkin I, Morgia G, et al. Prostatic artery embolization for prostate volume greater than 80 cm³: Results from a single-center prospective study. *Urology.* Elsevier Inc.; 2014;84(2):400–4.
26. Carnevale FC, Da Motta-Leal-Filho JM, Antunes A a., Baroni RH, Freire GC, Cerri LMO, et al. Midterm follow-up after prostate embolization in two patients with benign prostatic hyperplasia. *Cardiovasc Intervent Radiol.* 2011;34(6):1330–3.
27. Ahyai SA, Lehrich K, Kuntz RM. Holmium Laser Enucleation versus Transurethral Resection of the Prostate: 3-Year Follow-Up Results of a Randomized Clinical Trial. *Eur Urol.* 2007;52(5):1456–64.
28. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. *J Urol.* 2008;180(1):246–9.
29. Dørflinger T, Jensen FS, Krarup T, Walter S. Transurethral prostatectomy compared with incision of the prostate in the treatment of prostatism caused by small benign prostate glands. *Scandinavian journal of urology and nephrology.* 1992. p. 333–8.